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I. Summary 
The Scientific Committee on Consumer Products (SCCP) of European Commission 
concluded in its Draft Opinion on triclosan (SCCP/1040/06) of October 10th 2006 that:  
• On the basis of the available data, the SCCP is of the opinion that there is 
presently no evidence of clinical resistance and cross-resistance occurring from 
the use of triclosan in cosmetic products.  
• Although probable, this link has not been fully demonstrated.  
 
Since this conclusion differs from that made by The Norwegian Scientific Committee for 
Food Safety in its report of January 31st 2005, The Norwegian Food Safety Authority 
asked The Norwegian Scientific Committee for Food Safety, Panel on Biological 
Hazards to reconsider their conclusion in view of the SCCP draft opinion and recently 
published scientific literature.  
 
The Norwegian Scientific Committee for Food Safety, Panel on Biological Hazards 
concludes in this report that: 
• Neither the SSCP Draft Opinion on triclosan, nor recently published scientific 
literature, justifies rejection of our conclusions of January 31st 2005 (The 
Norwegian Scientific Committee for Food Safety, Panel on Biological Hazards 
report). 
• If anything, recent scientific literature supports the conclusions stated in the The 
Norwegian Scientific Committee for Food Safety, Panel on Biological Hazards 
report.    
• Triclosan use may elevate the risk of increased antimicrobial resistance (co- 
and/or cross–resistance) in clinically important bacteria. 
.  
The dilemma posed by this issue is that if precautions are not observed, then at the time 
point when evidence of clinical resistance and cross-resistance becomes available, it 
may already be too late to contain the problem effectively. Accordingly, the use of 
triclosan, along with that of other antimicrobial agents, should be limited to situations for 
which scientific data are available demonstrating obvious health benefits. 
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II. Sammendrag (norsk) 
Den Europa kommisjonens vitenskapskomité for forbruksvarer (SCCP) konkluderte 10. 
oktober 2006 med at det på grunnlag av tilgjengelige data ikke er funnet bevis for at 
triklosan i kosmetiske produkter kan føre til resistens – eller kryssresistensutvikling hos 
bakterier. Til tross for at en slik sammenheng kan være sannsynlig, finnes det ikke god 
dokumentasjon.  
 
Siden denne konklusjonen ikke svarer til Vitenskapskomiteen for mattrygghets (VMK) 
konklusjon av 31. januar 2005, har Mattilsynet bedt VMK om på nytt å vurdere 
konklusjonen i lys av SCCPs rapport og nyere litteratur.  
 
I denne rapporten konkluderer faggruppe for hygiene og smittestoffer ved VMK med at 
verken SSCPs rapport eller nyere litteratur gir grunnlag for å endre konklusjonen av 31. 
januar 2005. Tvert imot synes nyere litteratur å underbygge konklusjonen.  
 
Dilemmaet er at den dagen det foreligger dokumentasjon på resistensutvikling hos 
klinisk relevante bakterier som en følge av triklosanbruk, kan det være for sent for å 
avgrense problemet på en effektiv måte. Antimikrobielle stoffer som triklosan bør derfor 
bare benyttes i tilfeller der vitenskapelig dokumentasjon bekrefter at bruken gir en klar 
helsegevinst. Slik dokumentasjon etterlyses. 
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III. Background 
On October 10th 2006 The Scientific Committee on Consumer Products (SCCP) 
presented a Draft Opinion on triclosan (SSCP/1040/06). The SCCP Opinion on triclosan 
was prepared in response to a request from the Norwegian Food Safety Authority 
(Mattilsynet), asking for a re-evaluation of the safety of the use of triclosan in cosmetic 
products. This request was based on the report ”Risk assessment on the use of 
triclosan in cosmetics” (Norwegian Scientific Committee for Food Safety, 2005) which 
concluded:  
•  In some situations, particularly in clinical settings, triclosan is a useful, broad-spectrum 
biocide,  
• However, widespread use of triclosan, including in cosmetic products, selects for 
development of triclosan resistance, 
• Furthermore, such use represents a public health risk with regard to development of 
concomitant resistance to clinically important antimicrobial agents, 
• The assessment regarding use of triclosan in consumer products from 2002 
(Norwegian Institute of Public Health, 2000) seems strengthened by new evidence. 
  
In its draft opinion on triclosan, SCCP concluded that although probable, an association 
between increased occurrence of antibiotic cross-resistance and the use of biocides, 
including triclosan, has not been fully demonstrated (with reference to Aiello et al. 2004; 
and Cole et al. 2003).  
Concern about triclosan use is not only related to development of antimicrobial 
resistance in bacteria, but also to the fact that triclosan has commonly been found in 
human milk and plasma samples both in European countries (Allmyr et al. 2006b;Allmyr 
et al. 2006a) and in the US (Dayan 2007). Triclosan has also been found in the bile of 
fish experimentally exposed to municipal wastewater and in wild living fish from the 
recipient waters of wastewater treatment plants (Adolfsson-Erici et al. 2002). The 
toxicity of low concentrations of triclosan to certain fresh water algae with further 
influence on fresh water ecosystems has been pointed out as a matter of concern 
(Orvos et al 2002; Wilson et al 2003). 
  
IV. Terms of reference 
Based on the overall conclusions presented in SCCP/1040/06, The Norwegian Food 
Safety Authority (Mattilsynet) asked The Norwegian Scientific Committee for Food 
Safety, Panel on Biological Hazards to:  
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Evaluate whether the 11 references included in the SCCP opinion of October 10th 2006, 
but not included in our opinion of January 31st 2005, as well as other relevant, recently 
published scientific literature, provided further evidence that might affect the conclusion 
of the risk assessment performed by The Norwegian Scientific Committee for Food 
Safety, January 31st. 2005. In particular, focus should be directed towards how this 
literature might affect the conclusions regarding aspects of resistance. With this basis, 
The VKM was additionally requested to comment on the SCCP Draft Opinion on 
triclosan, and the conclusions reached therein. 
V. Opinion 
Development of antibiotic resistance in bacteria involves complex processes that are 
not fully understood. Continuous exposure of a large human population to antibacterial 
agents and prolonged exposure to sub-inhibitory concentrations are particularly 
worrying. Use and misuse of antibiotics are obviously very important factors, but high-
level resistance and multi-resistance development may be prolonged and involve 
various steps and events in different ecological niches.  For instance, the development 
of vancomycin resistance in enterococci was not detected until 1986, 31 years after the 
introduction of this antibiotic into clinical use. Likewise, penicillin-resistant pneumococci 
have developed over decades, from being reported from a few locations in the 1960s 
and 70s, to emerge as a worldwide clinical problem in the 1980s, significantly affecting 
patients with respiratory tract infections.  Mobile genetic elements may carry various 
resistance factors. In addition to inducing resistance to the drug itself, a substance may 
also select bacteria with resistance to other, clinically more important drugs. Even low-
grade resistance may entail such effects by giving the insensitive bacteria in normal 
flora selective advantages. Many members of the normal flora, such as Escherichia coli, 
Bacteroides spp., Stenothrophomonas maltophilia, and the pneumococci, are potential 
pathogens and under particular circumstances may give rise to clinical infections.   
  
VI. Remarks on SSCP’s opinion, - evaluation of 
recently published scientific literature 
Is there a rationale for adding triclosan to cosmetic or common household 
products?  
The rationale for using triclosan-containing products is based on whether beneficial 
effects can be anticipated, e.g. reduced incidence of contagious infectious diseases, or 
improved general or oral health. Any potentially beneficial effects must be considered 
against potential harmful effects, such as the risk of increase and/or spread of 
antimicrobial resistance. 
Are there any documented beneficial effects of adding triclosan to cosmetic 
products? 
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Proper hand hygiene is widely acknowledged as a critical element in an adequate 
infection control program. In a randomized, 48-week, double blind trial, intervention 
families were allocated use of triclosan-containing liquid soap and various house-
cleaning products containing antimicrobial agents. As no difference in prevalence of 
infectious disease symptoms was observed between the control and intervention 
groups, there was no obvious benefit of using triclosan (Larson et al. 2004). In a recent 
meta-analysis of six-month studies of antiplaque and antigingivitis agents, toothpastes 
containing triclosan (0.3 %) and Gantrez copolymer (2 %) had a significant beneficial 
effect on plaque and gingivitis. However, it was notable that triclosan combined with 
soluble pyrophosphate or zinc citrate showed no significant effect. Mouthrinses with 
0.12 % chlorhexidine were most efficacious, and showed the most consistent results 
(Gunsolley 2006). The ultimate goal of dental plaque control is to maintain oral health 
and to prevent periodontal disease and dental caries. However the level of plaque 
reduction required to prevent development, or to slow the progression of periodontitis or 
dental caries has not been fully ascertained, and the documentation for an additional 
beneficial effect of triclosan on periodontitis or dental caries has been reported as weak 
(Edwardsson et al. 2005).  
In a recent clinical study supported by Colgate-Palmolive, the antimicrobial effect of one 
week’s tooth-brushing with toothpaste containing triclosan, was still evident in saliva at 
12 h after brushing (twice daily) (Fine et al. 2006). The implication from this data is that 
a triclosan-containing dentifrice with such a formulation may exert a persistent selective 
pressure on the oral flora.   
Several studies have demonstrated that in ordinary use triclosan is, to some extent, 
absorbed and distributed to human tissues. As it is highly lipophilic, triclosan reaches 
the systemic circulation through the mucosal membranes of the oral cavity (Lin 2000), 
and the gastro-intestinal tract (Sandborgh-Englund et al. 2006). Toothpaste is the main 
source of the triclosan in human blood and milk samples  (Adolfsson et al. 2002; Allmyr 
et al. 2006a; Allmyr et al. 2006b; Dayan 2007), and concentrations vary considerably in 
the population. Studies of triclosan pharmacokinetics show an average half-life of 21h in 
plasma, which suggests that twice-daily tooth-brushing with a triclosan toothpaste will 
result in constant elevation of triclosan plasma levels. The finding that 24 to 83 % of an 
oral triclosan dose was excreted via the urine (Sandborgh-Englund et al. 2006) is also 
indicative of this elevation. These data suggest that when toothpaste contains triclosan, 
it will occur in various tissues of the user and the normal flora will be exposed to a range 
of triclosan concentrations. 
 
Resistance against triclosan, a reality not only in laboratory mutants 
Fan and co-workers (Fan et al. 2002) found that clinical isolates of Staphylococcus 
aureus with triclosan minimum inhibitory concentrations (MICs) of above 0.016 µg/ml 
showed an increase, of between three to fivefold, in their levels of enoyl-acyl carrier 
protein (ACP) reductase (Fab1). Thus, in addition to a mutation in the fabI gene, these 
altered genes were over-expressed in comparison to that observed in susceptible 
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strains. This publication is the first elucidating the mechanisms of triclosan resistance in 
clinically-derived isolates of this important pathogen.   
Schmid and Kaplan (Schmid and Kaplan 2004) examined reduced triclosan 
susceptibility among methicillin-resistant S. aureus and Staphylococcus epidermidis 
(CNS) strains. Decreased susceptibility to triclosan was found to be more prevalent 
among methicillin-resistant S. epidermidis isolates than among methicillin-resistant S. 
aureus isolates and the authors speculated that the mechanisms and frequencies of 
resistance might differ between S. epidermidis and S. aureus. Alternatively, this 
difference might be explained by greater exposure of S. epidermidis to triclosan, due to 
frequent skin contact with triclosan-containing antimicrobial products. S. epidermidis is 
considered a predominant resident skin bacterium, and is also a major nosocomial 
pathogen associated with implanted medical devices. S. aureus is most frequently 
carried in the nasal vestibulum in humans.  
Aiello et al. (2004) reported increased MICs in some isolates from household, clinical 
and industrial settings. Among them were S. aureus and coagulase-negative 
staphylococci, Staphylococcus capitis, S. epidermidis and Staphylococcus warneri. 
Some of the isolates (Acinetobacter baumannii, Enterobacter agglomerans, 
Enterobacter cloacae, Klebsiella pneumoniae, Pseudomonas fluoresecens and 
Pseudomonas putida) had triclosan MICs in the concentration range commonly used in 
consumer products.   
In a recent report (Wisniewska et al. 2006), triclosan MIC values were assayed in 100 
methicillin-resistant (MRSA) and 100 methicillin-sensitive (MSSA) clinical S. aureus 
isolates derived from 18 hospital laboratories in Poland between 2000 and 2004.  The 
MRSA isolates also demonstrated a diverse background of resistance patterns to other 
clinically important antibiotics. Methicillin resistance was confirmed by mecA PCR. The 
results show (Table 1) that the MIC50 and MIC90 to triclosan of the MRSA isolates 
were much higher than that of the MSSA isolates, and of the control strain. 
The results may indicate that MRSA isolates have a selective advantage over MSSA 
isolates during triclosan challenge. Although these findings need further confirmation, 
they are considered important in that they demonstrate increased triclosan resistance 
among clinical bacterial isolates.  
 
Table 1. Sensitivity of methicillin-resistant (MRSA) and methicillin-sensitive (MSSA) clinical S. 
aureus isolates towards triclosan (Wisniewska et al. 2006). (Translated from Polish) 
Triclosan MIC (mg/L) given as % of examined isolates Isolates No. 
0.03 0.06 0.12 0.25 0.5 1.0 2.0 MICST MIC50 MIC90
MRSA 100 30 0 0 0 4 4 62 1.3 2 2 
MSSA 100 93 4 0 0 0 0 3 0.09 0.031 0.031
Total 200 61.5 2 0 0 2 2 32.5 0.7 1.02 1.02 
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Small-colony variants (SCVs) of S. aureus are the cause of recurring and persistent 
infections, and often refractory to antimicrobial chemotherapy. This mode of 
antimicrobial resistance is poorly understood, but in vitro SCV evolution is observed in 
both MRSA and MSSA on Mueller-Hinton agar containing 1 mg/L triclosan (Seaman et 
al. 2007). Sequencing of the fabI gene excluded mutation in this target molecule. 
Triclosan selected for S. aureus colonies with low-level triclosan resistance and 
concomitant reduced susceptibility to penicillin and gentamicin. Further, the SCVs were 
shown to have increased tolerance to the bactericidal effect of triclosan. Such SCVs 
may have a selective advantage when exposed to triclosan. However, the extent to 
which isolates with decreased susceptibility to triclosan would develop and have the 
fitness to survive under clinical conditions, is as yet unknown. 
In one study (Brenwald and Fraise 2003), mentioned neither in our opinion nor in the 
SCCP’s opinion, two triclosan-selected mutants had a 4-fold and a 16-fold increase in 
triclosan MICs (1 mg/L and 4 mg/L, respectively). Four clinical isolates of MRSA were 
also detected with similar susceptibilities as these mutants. One selected mutant and 
one clinical isolate showed changes in their fabI genes. The other mutant and three 
clinical isolates lacked such changes, suggesting that genetic loci other than fabI may 
be involved in triclosan resistance. 
  
VII. Evaluation of 11 reports/scientific papers 
mentioned in the Draft opinion of SCCP /1040/06  
See Appendix 1 and Conclusions 
  
VIII- Conclusions 
Several publications on triclosan resistance have indicated the apparent lack of 
resistance development in clinical isolates after triclosan exposure in vivo. Emergence 
of bacterial resistance has repeatedly been shown to involve a substantial delay 
following introduction of new antimicrobial compounds. As testing for triclosan 
resistance is not routinely conducted in clinical laboratories assessing microbial therapy, 
triclosan resistance in clinical isolates may be less restricted than the data suggest.  
 
Toothpastes are the main source of triclosan exposure in humans. The use of triclosan 
in every day consumer products (including cosmetics) has questionable health 
benefits. Available data on beneficial health effects of triclosan-containing cosmetics or 
household products are not convincing. None of the 11 articles/reports mentioned in the 
SCCP opinion recommends use of triclosan in consumer products for general use.  
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Scientific assessment of the potential consequences associated with triclosan use 
should also consider possible detrimental environmental and ecotoxicological effects. 
These are well documented, but not further discussed in this report. 
In vitro studies have repeatedly revealed that several bacterial species have the 
potential to develop triclosan resistance. In addition, information on increased triclosan 
resistance in clinical isolates is emerging. These data should be considered in 
assessing the potential long-term effects of widespread triclosan use. The dilemma 
posed by this issue is that if precautions are not observed, then at the time point when 
evidence of clinical resistance and cross-resistance becomes available it may already 
be too late to contain the problem effectively. Accordingly, the use of triclosan, along 
with other antimicrobial agents, should be limited to situations for which scientific data 
are available demonstrating obvious health benefits. 
 
The main conclusions are: 
 
• Neither the SSCP Draft Opinion on triclosan, nor recently published scientific 
literature, justifies rejection of our conclusions of January 31st 2005 (The 
Norwegian Scientific Committee for Food Safety, Panel on Biological Hazards 
report). 
• If anything, recent scientific literature support the conclusions stated in the The 
Norwegian Scientific Committee for Food Safety, Panel on Biological Hazards 
report.  
• Triclosan use may elevate the risk of increased antimicrobial resistance (co- 
and/or cross–resistance) in clinically important bacteria. 
.  
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IX-Appendix I 
Brief review of literature referred to by the Scientific Committee on Consumer Products 
(SCCP) in the Draft Opinion on triclosan (SSCP/1040/06), with focus on risk 
assessment on use of triclosan in cosmetics: 
  
1. BfR, Federal Institute for Risk Assessment, Germany. 2006. Triclosan nur im 
ärztlichen Bereich anwenden, um Resistenzbildungen vorzubeugen, Stellungnahme 
Nr. 030/2006 des BfR vom 08. Mai 2006.  
 
and 
2. BfR (Federal Institute for Risk Assessment, Germany). 2006. Triclosan only belongs 
in the clinic and doctor’s surgery! (Press release). 
These two publications give an overview on triclosan and its applications, the 
mechanisms and epidemiology of triclosan resistance, and possible implications. A 
statistically significant increase in resistance among pathogens isolated from the 
environment is not demonstrated after the application of triclosan in household 
products. However, a tendency to increased resistance towards quinolones and 
tetracyclines is indicated. According to the risk assessment by BfR, triclosan should be 
used very restrictively and with the necessary degree of caution.  Furthermore the 
precautionary principal regarding consumer safety, as recommended by WHO, should 
be enforced.   
3. Braoudaki, M and A.C. Hilton. 2005. Mechanisms of resistance in Salmonella 
enterica adapted to erythromycin, benzalkonium chloride and triclosan. International 
Journal of Antimicrobial Agents. 25:31-37. 
Adaptation of the Salmonella enterica serovars Enteritidis, Typhimurium and Virchow to 
sub-MIC concentrations of the antimicrobial agents included different active efflux 
systems and increased cell surface hydrophobicity, which could contribute to 
antimicrobial resistance. The response is dependent on the specific strain/antimicrobial 
involved and is therefore difficult to predict.        
4. Champlin, F.R., M.L. Ellison, J.W. Bullard and R.S. Conrad. 2005. Effect of outer 
membrane permeabilization on intrinsic resistance to low Triclosan levels in 
Pseudomonas aeruginosa. International Journal of Antimicrobial Agents 26, 159-164. 
The outer membrane of P. aeruginosa has an intrinsic resistance mechanism to low 
concentrations of triclosan. The impermeability of the outer cell envelope of P. 
aeruginosa is suggested to play a role in resistance to higher concentrations of 
triclosan.  
5. Cookson, B. 2005. Clinical significance of emergence of bacterial antimicrobial 
resistance in the hospital environment. Journal of Applied Microbiology, 99, 989-996. 
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This review article outlines antimicrobial resistance among microorganisms causing 
hospital infections. The author emphasizes: “Although resistance to antibiotics has been 
addressed in many strategies and publications, the complex issue and importance of 
biocide resistance has not achieved as high a profile...” The author states: “There are 
many confounding factors that plague any discussions relating to biocide resistance”. 
As “There is no international consensus on biocide efficacy tests or approved product 
registers...”, , “Unlike antibiotic resistance, the issue relating to biocide resistance has a 
very low profile and priority... This low priority is also reflected in the lack of funding of 
biocide research projects in most countries. 
”Another deficiency is that studies often fail to identify the biocide resistance 
mechanism, its genetic nature or location. This is no doubt related to the lack of 
investment outlined above.“  
6. Cole, E.C., R.M. Addison, J.R. Rubio, K.E. Leese, P.D. Dulaney, M.S. Newell, J. 
Wilkins, D.J. Gaber, T. Wineinger and D.A. Criger. 2003. Investigation of antibiotic and 
antibacterial agent cross-resistance in target bacteria from homes of antibacterial 
product users and nonusers. Journal of Applied Microbiology 95, 664-676. 
The aim of the study was “…to describe the relationship between antibiotic and 
antibacterial resistance in environmental and clinical bacteria from home environments 
across geographic locations, relative to the use or non-use of antibacterial products, 
with focus on target organisms recognised as potential pathogens”. 
Among a total of 1238 bacterial isolates, 197 isolates were from clinical sites, hands or 
oral cavities, and two samples were collected from one to two individuals of each family.  
“The results showed lack of antibiotic and antibacterial agent cross-resistance in target 
bacteria from homes of antibacterial product users and non-users, as well as increased 
prevalence of potential pathogens in non-user homes.” The authors judged the 
significance and impact of the study as follows: “It refutes widely publicised, yet 
unsupported, hypotheses that use of antibacterial products facilitate the development of 
antibiotic resistance in bacteria from the home environment”.  
Although the study included 30 families that used antibacterial products and 30 non-
user families, and a large number of bacterial samples were collected, the number of 
clinical isolates investigated was relatively low. Furthermore, it is unclear how previous 
exposure to triclosan was controlled.   
Whilst the study revealed no association between use of antibacterial products and the 
prevalence of resistant bacteria, the high number of resistant strains detected in both 
groups is worrying. In both study groups, 75-77 % of environmental bacteria were 
resistant to one or more antibiotics, and among the clinical isolates, 52-57% strains 
were resistant. Could this possibly reflect a universal, inadvertent, high exposure to 
triclosan and other antibacterial products? Regarding which bacterial groups were 
resistant, differences between the product users and non-users were not detected, 
except with respect to viridans streptococci, with three times more resistant viridans 
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Streptococcus isolates among users than non-users (19.6% versus 6.3 %). Viridans 
streptococci constitute a major proportion of the oral flora and represent an important 
reservoir of antimicrobial resistance genes that might be transferred to other bacteria, 
e.g. the clinically important pneumococci (Spratt 1993,Bryskier 2002). 
  
7. Dixon, B, 2005. Selective agencies. ASM News, 71:310-311. A commentary/ review 
note.  
 
Agents (culinary herbs, chemotherapeutic drugs and copper) other than antimicrobials 
can exert selective pressures, favouring the proliferation of organisms insensitive to 
antimicrobials. 
 
8. Glaser, A. 2004. The ubiquitous Triclosan. A common antibacterial agent exposed. 
Pesticides and You. 24, 12- 17. 
Glaser raises the concern of resistance development and concludes that triclosan in 
cosmetic and household products is unnecessary and adds no health benefits.   
9. Kampf, G. and A. Kramer. 2004. Epidemiologic background of hand hygiene and 
evaluation of the most important agents for scrubs and rubs. Clinical Microbiological 
Reviews. 17:863-893. 
This review article from 2004 gives an extensive overview on the epidemiology of hand 
hygiene and important agents used in this respect. Triclosan is one of the agents 
covered. Several of the original scientific publications included in this review article 
demonstrate development of cross-resistance to other clinically significant antibacterial 
agents occurs after in vitro exposure to triclosan. The authors conclude that no 
conclusive link between triclosan usage and antibiotic resistance development in clinical 
isolates has been shown. However, the article also refers to studies that show high 
prevalence of triclosan resistance in samples of compost, water and soil, in which the 
widespread use of triclosan in consumer products is proposed as the probable 
explanation.       
10. Russel, A.D. 2004. Whither Triclosan ? Journal of Antimicrobial Chemotherapy. 53, 
693-695. 
The basis for this Leading article is that environmental surveys to date have not 
demonstrated any association between triclosan usage and antibiotic resistance. There 
are many unanswered questions regarding the consequences of widespread use of 
triclosan, and the future aim should be to retain the important and valuable applications 
of triclosan, whilst eliminating the unnecessary ones.       
The author states: …there is no convincing evidence to support the contention that 
triclosan usage has resulted in the clinical development of antibiotic-resistant (…) 
bacteria (…). Nevertheless, it would be wise to restrict the use of triclosan to areas 
where it has been shown to be effective.” 
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 11. Sánchez, P., E. Moreno and J.L. Martínez. 2005. The biocide Triclosan selects 
Stenotrophomonas maltophilia mutants that overproduce the SmeDEF mutidrug efflux 
pump. Antimicrobial Agents and Chemotherapy. 49, 781-782. 
Triclosan can select triclosan-resistant mutants of the opportunistic human pathogen 
Stenotrophomonas maltophilia. These mutants over-express the multi-drug resistance 
pump SmeDEF. S. maltophilia is a problematic microorganism in patients suffering from 
cystic fibrosis, and in transplantation patients. In vitro studies are useful for 
predicting the capability of an organism to develop resistance in the future. The authors 
refer to (Russell 2004): ”there remain concerns about the unnecessary use of triclosan 
and other biocides in the home and in clinical setting.” 
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